Showing 2711-2720 of 5771 results for "".
- Ashvattha Therapeutics Reports Positive Phase 2 Results for Potential First-in-Class Treatment for DME and Wet AMDhttps://modernod.com/news/ashvattha-therapeutics-reports-positive-phase-2-results-for-potential-first-in-class-treatment-for-dme-and-wet-amd/2484136/Ashvattha Therapeutics announced positive topline results from its phase 2 study of migaldendranib (MGB) in diabetic macular edema (DME) and wet age-related macular degeneration (AMD) at the Euretina Congress. MGB is
- AAVantgarde Bio Presents Clinical Data from LUCE-1 Gene Therapy Trial in Usher Syndrome Type 1Bhttps://modernod.com/news/aavantgarde-bio-presents-clinical-data-from-luce-1-gene-therapy-trial-in-usher-syndrome-type-1b/2484135/AAVantgarde Bio announced updated clinical results from its ongoing LUCE-1 phase 1/2 study of AAVB-081, presented at the 25th European Society of Retina Specialists (EURETINA) annual congress in Paris. The LUCE-1 study
- PulseSight Therapeutics to Present New Data on Iron Dysregulation and Ferroptosis in AMD at Euretina 2025https://modernod.com/news/pulsesight-therapeutics-to-present-new-data-on-iron-dysregulation-and-ferroptosis-in-amd-at-euretina-2025/2484133/PulseSight Therapeutics announced that its Chief Scientific Officer, Thierry Bordet, PhD, will present new clinical and preclinical findings on the role of iron dysregulation and ferroptosis in age-related macular degeneration (AMD) at the 25th Euretina Congre
- Contact Lens Institute Extends Partnership with Actress Kate Flannery for The EASY Way Campaignhttps://modernod.com/news/contact-lens-institute-extends-partnership-with-actress-kate-flannery-for-the-easy-way-campaign/2484132/The Contact Lens Institute (CLI) announced the continuation of its partnership with actress and comedian Kate Flannery to promote 'The EASY Way,' an initiative that aims to help eye care professionals encourage healthy contact lens wear-and-care b
- Nanoscope Secures EMA Orphan Designations and FDA RMAT Status for Retinal Gene Therapy MCO-010https://modernod.com/news/nanoscope-secures-ema-orphan-designations-and-fda-rmat-status-for-retinal-gene-therapy-mco-010/2484130/Nanoscope Therapeutics announced regulatory milestones in both Europe and the United States for its lead gene therapy candidate, MCO-010 (sonpiretigene isteparvovec). The European Medicines Agency (EMA) has granted Orphan D
- Nanoscope to Present Long-Term Data for MCO-010 in RP at Euretina and Retina Society 2025https://modernod.com/news/nanoscope-to-present-long-term-data-for-mco-010-in-rp-at-euretina-and-retina-society-2025/2484129/Nanoscope Therapeutics announced it will present new long-term data from its RESTORE follow-up study, REMAIN, at two major international meetings: the 2025 Euretina Congress in Paris and the 2025 Retina Society Annual Scientific Meeting in Chicago.
- jCyte Initiates Patient Dosing in Phase 2 JC02-88 Trial of jCell for RPhttps://modernod.com/news/jcyte-initiates-patient-dosing-in-phase-2-jc02-88-trial-of-jcell-for-rp/2484125/jCyte announced that the first patients have been enrolled and treated in the JC02-88 study, a phase 2 clinical trial evaluating the safety and efficacy of jCell (famzeretcel) for the treatment of retinitis pigmentosa (RP). The study is testing a jCell dose about 5
- FDA Clears IND for Opus Genetics’ OPGx-BEST1 Gene Therapy Candidatehttps://modernod.com/news/fda-clears-ind-for-opus-genetics-opgx-best1-gene-therapy-candidate/2484123/Opus Genetics announced that the FDA has accepted its investigational new drug (IND) application for OPGx-BEST1, a gene therapy for the treatment of bestrophin-1 (BEST1)-related inherited retinal diseases (IRDs). The company now plans to initiate a Phase 1/2 clinical trial in the second
- Myra Vision Secures FDA Approval to Initiate US-Based IDE Study in Glaucomahttps://modernod.com/news/myra-vision-secures-fda-approval-to-initiate-us-based-ide-study-in-glaucoma/2482933/Myra Vision announced today that the FDA has issued a conditional approval letter for its investigational device exemption (IDE) application, allowing the company to initiate the ADAPT study. The prospective, nonr
- Beyeonics Vision Secures US Patent for Ophthalmic Surgical Visualization Technologyhttps://modernod.com/news/beyeonics-vision-secures-us-patent-for-ophthalmic-surgical-visualization-technology/2482931/Beyeonics Vision announced the issuance of a US patent to protect its core technology for how surgeons visualize the eye during cataract and other ocular procedures. According to Beyeonics, the patent, titled “Systems and Methods for Imaging a